



JOIN LILLY'S FIRST CLL MEETING IN LISBON!

[CLICK HERE TO CONFIRM YOUR ATTENDANCE](#)

Please contact the medical department:
de_esteban_laura@lilly.com



Iberian Bloodlines is just around the corner, and we'd love for you to be part of it! This is a unique opportunity to exchange insights on **chronic lymphocytic leukemia** (CLL) with top experts from Spain and Portugal.



MARCH 28-29, 2025
Hotel Tivoli Oriente

Av. Dom João II, 1990-083 Lisbon, Portugal

With the scientific endorsement of:



Sociedad Española de Hematología y Hemoterapia

OUR EXPERT PANEL INCLUDES:



PROF. MARIA GOMES DA SILVA
Portugal



DR. JOSÉ PEDRO CARDA
Portugal



DR. LUCRECIA YÁÑEZ
Spain



DR. JOSÉ ÁNGEL HERNÁNDEZ
Spain

Schedule

FRIDAY, MARCH 28

19:00

Welcome Dinner

SATURDAY, MARCH 29

10:00 - 10:05

Lilly Medical Department Portugal & Spain.

Welcome and Introduction

10:05 - 11:00

Sequencing CLL treatment and guidelines

1. Fixed duration 1L treatment updates · Prof. Maria Gomes Da Silva.
2. Refractoriness and relapse setting. Outcomes post non-covalent BTKi · Dr. José Ángel Hernández Rivas.
3. Novel emergent treatments · Dr. Lucrecia Yáñez. General discussion.

11:00 - 11:20

Clinical case I: Complex case of a heavily pretreated TP53mut refractory patient post-cBTKi.

Dr. José Pedro Carda.

11:20 - 12:00

Controversies I: After cBTKi relapse, will most of the patients benefit from non-covalent inhibition?

Introduction · Prof. Maria Gomes Da Silva.

- Posture A: The importance of exhausting the BTK pathway before switching therapeutic classes · Dr. Lucrecia Yáñez.
- Posture B: Early transition to venetoclax as a better approach · Dr. José Pedro Carda.
- Small group discussions.
- General debate and conclusion · Dr. José Ángel Hernández Rivas.

12:00 - 12:20

Coffee Break

12:20 - 12:40

Clinical case II: When a patient is intolerant to a cBTKi, can we reestablish the BTK pathway with a non covalent BTKi?

Dr. José Ángel Hernández Rivas.

12:40 - 13:20

Controversies II: Patient and Clinician preferences.

Introduction · Prof. Maria Gomes Da Silva.

Discussion on Real-Life Clinical Scenarios.

- Scenario 1 · Dr. José Pedro Carda.
- Scenario 2 · Dr. Lucrecia Yáñez.
- Scenario 3 · Prof. Maria Gomes Da Silva.
- Scenario 4 · Dr. José Ángel Hernández Rivas.

13:20 - 13:30

Closing Remarks

- Final answers to the questions collected · Dr. José Pedro Carda.
- Summary of key learnings and next steps · Prof. Maria Gomes Da Silva.

13:30

Lunch